Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.33% | 85.29% | 74.88% | 68.31% | 40.32% |
| Total Depreciation and Amortization | -20.23% | -1.94% | 16.29% | 12.95% | 3.79% |
| Total Amortization of Deferred Charges | 31.38% | 14.52% | -7.86% | -22.11% | -29.50% |
| Total Other Non-Cash Items | 362.42% | 696.84% | 41.09% | -37.87% | -56.18% |
| Change in Net Operating Assets | -254.66% | -471.97% | -288.89% | -485.39% | 468.29% |
| Cash from Operations | 36.22% | 76.82% | 62.05% | 65.31% | 47.97% |
| Capital Expenditure | -- | -- | -- | 14.90% | -134.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.15% | -98.41% | 887.76% | 1,076.74% | 249.59% |
| Cash from Investing | -118.24% | -98.39% | 834.95% | 1,042.32% | 248.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -38.36% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 7,012,300.00% | -17.98% | -- | -100.00% |
| Repurchase of Common Stock | -376.21% | -376.21% | 67.41% | 65.49% | 69.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -212.00% | -486.67% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -150.72% | -- | -- | 99.92% | -126.75% |
| Cash from Financing | 283.12% | 2,642.28% | -120.35% | -119.16% | -119.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -164.01% | 112.50% | -107.54% | 228.28% | 122.12% |